Product

TLC599 HD

Aliases

18 mg DSP with 150 µmol PL (1.5 mL), TLC599 HD group

1 clinical trial

1 indication

Indication

Osteoarthritis of the Knee

Clinical trial

A Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for Single Dose Administration of TLC599 in Patients With Osteoarthritis (OA) of Knee

Status: Completed, Estimated PCD: 2018-07-04